A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NGVT SEC filings page.
Ingevity Corporation (NGVT) reported $1.1B in revenue over the twelve months to Sep 30, 2026, down 3.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Ingevity's operating engine retains cash generation as sales shrink, but balance-sheet leverage now dominates the financial picture.
Revenue fell30.0% from FY2022 to FY2025, yet operating income fell only7.5% , showing the business retained much of its operating earnings as volume contracted. Operating margin expanded from27.1% to35.9% , pointing to cost structure or mix doing more work than volume rather than growth carrying profitability.
FY2025 paired a net loss of
The balance sheet is highly liability-funded: liabilities were
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Ingevity Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Ingevity Corporation scores 92/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Ingevity Corporation scores 24/100 on it among other operating companies.
Ingevity Corporation's net debt of $1.1B, being $1.2B of long-term debt less $78.1M of cash, came to 2.06 times its EBITDA in fiscal year 2025. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Ingevity Corporation scores 43/100 among other operating companies measured the same way.
Ingevity Corporation held $1.33 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.33. Liquidity ranks operating companies on that ratio, and Ingevity Corporation scores 36/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Ingevity Corporation scores 77/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Ingevity Corporation scores 90/100 on it among other operating companies.
Ingevity Corporation scores 2.71, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from operating income of $418.7M against total assets of $1.7B. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Ingevity Corporation passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Ingevity Corporation reported a net loss of $167.1M while generating $331.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Ingevity Corporation earns $5.35 in operating income for every $1 of interest expense ($418.7M vs $78.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Ingevity Corporation generated $305.1M in revenue in Q3 2026. This represents a decrease of 8.4% from the same quarter a year earlier. Against the prior quarter it is down 2.9%.
Ingevity Corporation reported $49.3M in net income in Q3 2026. This represents an increase of 13.3% from the same quarter a year earlier. Against the prior quarter it is up 39.7%.
Ingevity Corporation earned $1.41 per diluted share (EPS) in Q3 2026. This represents an increase of 19.5% from the same quarter a year earlier. Against the prior quarter it is up 41.0%.
Not reported for Q3 2026.
Cash & Balance Sheet
Ingevity Corporation generated $85.5M in free cash flow in Q3 2026, representing cash available after capex. This represents a decrease of 27.4% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Ingevity Corporation held $85.4M in cash against $989.1M in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Ingevity Corporation's gross margin was 43.5% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 3.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.7 percentage points.
Ingevity Corporation's net profit margin was 16.2% in Q3 2026, showing the share of revenue converted to profit. This is up 3.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.9 percentage points.
Ingevity Corporation's quarterly ROE was 78.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 46.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.0 percentage points.
Not reported for Q3 2026.
Capital Allocation
Ingevity Corporation invested $8.3M in research and development in Q3 2026. This represents an increase of 18.6% from the same quarter a year earlier. Against the prior quarter it is up 36.1%.
Ingevity Corporation spent $38.5M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 52.8% from the same quarter a year earlier. Against the prior quarter it is up 11.6%.
Ingevity Corporation invested $13.7M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 15.1% from the same quarter a year earlier. Against the prior quarter it is up 33.0%.
NGVT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $305.1M-8.4% | $314.1M-5.2% | $258.0M+4.1% | $255.1M-3.1% | $333.1M-0.2% | $331.5M-15.1% | $247.9M-27.1% | $263.3M-29.2% |
| Cost of Revenue | $172.3M-13.5% | $175.1M-14.0% | $141.6M+4.1% | $167.2M+2.3% | $199.2M-1.5% | $203.7M-23.8% | $136.0M-43.4% | $163.4M-47.7% |
| Gross Profit | $132.8M-0.8% | $139.0M+8.8% | $116.4M+4.0% | $87.9M-12.0% | $133.9M+1.7% | $127.8M+3.7% | $111.9M+12.2% | $99.9M+67.9% |
| R&D Expenses | $8.3M+18.6% | $6.1M-12.9% | $6.7M-4.3% | $7.4M+13.8% | $7.0M+12.9% | $7.0M-4.1% | $7.0M+2.9% | $6.5M-9.7% |
| SG&A Expenses | $38.1M-13.6% | $39.0M-10.6% | $40.7M-2.9% | $41.6M+8.6% | $44.1M+16.4% | $43.6M+5.3% | $41.9M-11.2% | $38.3M-11.8% |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $80.6M+30.4% |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $105.8M+14.4% |
| Interest Expense | $13.5M-26.6% | $14.2M-23.7% | $15.9M-18.0% | $21.9M-23.2% | $18.4M-22.7% | $18.6M-19.8% | $19.4M-13.0% | $28.5M |
| Income Tax | $17.8M-16.8% | $10.9M+127.1% | $6.8M-20.0% | -$26.5M-688.9% | $21.4M+229.2% | $4.8Mn/m | $8.5Mn/m | $4.5Mn/m |
| Net Income | $49.3M+13.3% | $35.3Mn/m | $59.8M+191.7% | -$84.6M-609.6% | $43.5Mn/m | -$146.5Mn/m | $20.5Mn/m | $16.6Mn/m |
| EPS (Basic) | $1.44+20.0% | $1.02n/m | $1.70+203.6% | -$2.34-608.7% | $1.20n/m | -$4.02n/m | $0.56n/m | $0.46n/m |
| EPS (Diluted) | $1.41+19.5% | $1.00n/m | $1.66+196.4% | -$2.34-608.7% | $1.18n/m | -$4.02n/m | $0.56n/m | $0.46n/m |
| Diluted Shares (Avg) | 35M-5.7% | 35M-3.2% | 36M-1.8% | N/A | 37M+1.3% | 36M+0.3% | 37M+1.1% | N/A |
NGVT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.5B-18.0% | $1.5B-18.1% | $1.7B-19.7% | $1.7B-18.4% | $1.8B-17.1% | $1.9B-17.5% | $2.1B-19.9% | $2.0B-22.9% |
| Current Assets | $531.7M+1.8% | $543.8M+1.5% | $581.8M+9.8% | $454.2M-7.9% | $522.2M-18.0% | $536.0M-21.8% | $530.0M-20.8% | $493.2M-25.1% |
| Cash & Equivalents | $85.4M+2.4% | $97.4M+26.7% | $95.4M+33.4% | $78.1M+14.9% | $83.4M-38.5% | $76.9M-28.4% | $71.5M-19.2% | $68.0M-29.1% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $153.9M-20.5% | $154.0M-30.1% | $203.6M-17.0% | $186.0M-5.1% | $193.7M-25.8% | $220.3M-27.1% | $245.4M-24.6% | $195.9M-36.6% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $4.3M0.0% | $4.3M0.0% | $4.3M-97.6% | $4.3M-97.5% | $4.3M-97.7% | $4.3M-97.6% | $180.7M-65.6% | $175.2M-66.8% |
| Total Liabilities | $1.4B-15.1% | $1.5B-15.2% | $1.6B-11.5% | $1.6B-11.3% | $1.7B-15.1% | $1.8B-11.8% | $1.8B-8.9% | $1.8B-8.3% |
| Current Liabilities | $359.0M-12.8% | $337.6M-14.1% | $409.4M+54.7% | $341.3M+29.2% | $411.6M+14.1% | $393.1M+9.9% | $264.6M-24.8% | $264.1M-27.2% |
| Non-Current Liabilities | $1.1B-15.8% | $1.2B-15.5% | $1.2B-22.8% | $1.3B-18.1% | $1.3B-21.5% | $1.4B-16.5% | $1.6B-5.5% | $1.6B-4.0% |
| Long-Term Debt | $989.1M-14.6% | $1.1B-14.5% | $1.1B-18.8% | $1.2B-13.3% | $1.2B-17.1% | $1.2B-11.8% | $1.3B-5.4% | $1.3B-3.1% |
| Total Equity | $63.0M-54.4% | $46.9M-61.1% | $38.9M-83.4% | $29.7M-84.8% | $138.1M-35.6% | $120.7M-57.6% | $234.6M-58.7% | $195.2M-69.1% |
| Retained Earnings | $549.3M+12.2% | $500.0M+12.1% | $464.7M-21.6% | $404.9M-29.2% | $489.5M-11.9% | $446.0M-32.7% | $592.5M-37.4% | $572.0M-42.9% |
Not reported in any period shown, so not listed: Accounts Receivable.
NGVT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $99.2M-23.5% | -$13.8M-117.5% | -$2.0M-107.9% | $97.1M+50.5% | $129.7M+178.9% | $79.0M+166.0% | $25.4Mn/m | $64.5M+39.6% |
| Depreciation & Amortization | $20.9M-25.4% | $22.0M-14.1% | $22.7M-8.8% | $27.9M+10.7% | $28.0M+6.9% | $25.6M-6.2% | $24.9M-15.9% | $25.2M-17.9% |
| Stock-Based Compensation | N/A | N/A | $4.8M+17.1% | N/A | N/A | N/A | $4.1M-4.7% | N/A |
| Capital Expenditures | $13.7M+15.1% | $10.3M-15.6% | $10.3M+3.0% | $23.6M-5.2% | $11.9M-33.9% | $12.2M-32.6% | $10.0M-39.8% | $24.9M-14.7% |
| Free Cash Flow | $85.5M-27.4% | -$24.1M-136.1% | -$12.3M-179.9% | $73.5M+85.6% | $117.8M+313.3% | $66.8M+475.9% | $15.4Mn/m | $39.6M+132.9% |
| Investing Cash Flow | -$11.2Mn/m | $75.4Mn/m | $106.3Mn/m | -$15.1Mn/m | -$28.1Mn/m | -$2.8Mn/m | -$11.5Mn/m | -$28.0Mn/m |
| Financing Cash Flow | -$93.7Mn/m | -$37.6Mn/m | -$61.8Mn/m | -$83.4Mn/m | -$94.8Mn/m | -$63.0M-711.7% | -$11.0M-147.0% | -$97.6Mn/m |
| Share Buybacks | $38.5M+52.8% | $34.5Mn/m | $52.3Mn/m | $31.1Mn/m | $25.2Mn/m | $0n/m | $0n/m | $0n/m |
Not reported in any period shown, so not listed: Dividends Paid.
NGVT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 43.5%+3.3pp | 44.3%+5.7pp | 45.1%0.0pp | 34.5%-3.5pp | 40.2%+0.8pp | 38.6%+7.0pp | 45.1%+15.8pp | 37.9%+21.9pp |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 30.6%+14.0pp |
| Net Margin | 16.2%+3.1pp | 11.2%+55.4pp | 23.2%+14.9pp | -33.2%-39.5pp | 13.1%+45.2pp | -44.2%+28.4pp | 8.3%+24.7pp | 6.3%+37.7pp |
| Return on Equity | 78.3%+46.8pp | 75.3%+196.6pp | 153.7%+145.0pp | -284.8%-293.3pp | 31.5%+81.5pp | -121.4%-21.8pp | 8.7%+18.6pp | 8.5%+27.0pp |
| Return on Assets | 3.3%+0.9pp | 2.3%+10.1pp | 3.6%+2.6pp | -5.1%-5.9pp | 2.4%+7.2pp | -7.8%+4.7pp | 1.0%+3.2pp | 0.8%+5.3pp |
| Current Ratio | 1.48+0.2x | 1.61+0.2x | 1.42-0.6x | 1.33-0.5x | 1.27-0.5x | 1.36-0.6x | 2.00+0.1x | 1.87+0.1x |
| Debt-to-Equity | 15.70+7.3x | 22.52+12.3x | 27.83+22.1x | 39.10+32.2x | 8.39+1.9x | 10.24+5.3x | 5.68+3.2x | 6.86+4.7x |
| Liabilities-to-Equity | 22.86+10.6x | 31.78+17.2x | 41.42+33.7x | 54.59+45.2x | 12.28+3.0x | 14.56+7.6x | 7.76+4.2x | 9.36+6.2x |
| Asset Turnover | 0.200.0x | 0.200.0x | 0.160.0x | 0.150.0x | 0.180.0x | 0.180.0x | 0.120.0x | 0.130.0x |
| FCF Margin | 28.0%-7.3pp | -7.7%-27.8pp | -4.8%-11.0pp | 28.8%+13.8pp | 35.4%+26.8pp | 20.2%+17.2pp | 6.2%+14.7pp | 15.0%+10.5pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Ingevity Corporation NGVT | FY2025 | $1.2B | -$167.1M | -14.3% | $2.0B | 60/100 |
| The Chemours Company CC | FY2025 | $5.8B | -$386.0M | -6.7% | $1.8B | 27/100 |
| Quaker Houghton KWR | FY2025 | $1.9B | -$2.5M | -0.1% | $2.6B | 44/100 |
| H.B. Fuller Company FUL | FY2025 | $3.5B | $152.0M | 4.4% | $2.6B | 50/100 |
| Cabot Corporation CBT | FY2025 | $3.7B | $331.0M | 8.9% | $3.8B | 61/100 |
| Ashland Inc. ASH | FY2025 | $1.8B | -$845.0M | -46.3% | $3.4B | 36/100 |
Where Ingevity Corporation Ranks
Frequently Asked Questions
Ingevity Corporation (NGVT) reported $1.2B in total revenue for fiscal year 2025. This represents a -2.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Ingevity Corporation (NGVT) revenue declined by 2.7% year-over-year, from $1.2B to $1.2B in fiscal year 2025.
Yes, Ingevity Corporation (NGVT) reported a net income of $59.8M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $167.1M, with a net profit margin of -14.3%.
Ingevity Corporation (NGVT) had EBITDA of $525.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Ingevity Corporation (NGVT) had $78.1M in cash and equivalents against $1.2B in long-term debt.
Ingevity Corporation (NGVT) had a gross margin of 39.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Ingevity Corporation (NGVT) had an operating margin of 35.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Ingevity Corporation (NGVT) had a net profit margin of -14.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Ingevity Corporation (NGVT) has a return on equity of -562.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Ingevity Corporation (NGVT) generated $273.5M in free cash flow during fiscal year 2025. This represents a 436.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Ingevity Corporation (NGVT) generated $331.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
Ingevity Corporation (NGVT) had $1.7B in total assets as of fiscal year 2025, including both current and long-term assets.
Ingevity Corporation (NGVT) invested $57.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Ingevity Corporation (NGVT) invested $28.4M in research and development during fiscal year 2025.
Ingevity Corporation (NGVT) had a current ratio of 1.33 as of fiscal year 2025, which is considered adequate.
Ingevity Corporation (NGVT) had a debt-to-equity ratio of 39.10 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Ingevity Corporation (NGVT) had a liabilities-to-equity ratio of 54.59 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Ingevity Corporation (NGVT) had a return on assets of -10.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Ingevity Corporation (NGVT) trades at 33.5x earnings, its market capitalization divided by $59.8M net income, trailing 12 months to September 30, 2026. The market capitalization is $2.0B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Ingevity Corporation (NGVT) trades at 1.8x sales, its market capitalization divided by $1.1B revenue, trailing 12 months to September 30, 2026. The market capitalization is $2.0B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Ingevity Corporation (NGVT) has an Altman Z-Score of 2.71, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Ingevity Corporation (NGVT) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Ingevity Corporation (NGVT) reported a net loss of $167.1M while generating $331.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Ingevity Corporation (NGVT) has an interest coverage ratio of 5.35x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Ingevity Corporation (NGVT) scores 60 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.